公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2016 | Alectinib in crizotinib-refractory alk-rearranged non-small-cell lung cancer: A phase II global study | Ou S.-H.I; Ahn J.S; De Petris L; Govindan R; CHIH-HSIN YANG ; Hughes B; Lena H; Moro-Sibilot D; Bearz A; Ramirez S.V; Mekhail T; Spira A; Bordogna W; Balas B; Morcos P.N; Monnet A; Zeaiter A; Kim D.-W. | Journal of Clinical Oncology | 545 | 490 | |
2021 | Amivantamab in egfr exon 20 insertion- mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the chrysalis phase i study | Park K.; Haura E.B.; Leighl N.B.; Mitchell P.; Shu C.A.; Girard N.; Viteri S.; Han J.-Y.; Kim S.-W.; Lee C.K.; Sabari J.K.; Spira A.I.; Yang T.-Y.; Kim D.-W.; Lee K.H.; Sanborn R.E.; Trigo J.; Goto K.; Lee J.-S.; CHIH-HSIN YANG ; Govindan R.; Bauml J.M.; Garrido P.; Krebs M.G.; Reckamp K.L.; Xie J.; Curtin J.C.; Haddish-Berhane N.; Roshak A.; Millington D.; Lorenzini P.; Thayu M.; Knoblauch R.E.; Cho B.C. | Journal of Clinical Oncology | 298 | 226 | |
2022 | ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges | Chow L.Q.M.; Barlesi F.; Bertino E.M.; Van Den Bent M.J.; Wakelee H.A.; Wen P.Y.; Chiu C.-H.; Orlov S.; Chiari R.; Majem M.; McKeage M.; CHONG-JEN YU ; Garrido P.; Hurtado F.K.; Arratia P.C.; Song Y.; Branle F.; Shi M.; Kim D.-W. | Clinical Cancer Research | 19 | 14 | |
2020 | Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC | Tan W.L.; Chua K.L.M.; CHIA-CHI LIN ; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; YCHIH-HSIN YANG ; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. | Journal of Thoracic Oncology | 33 | 30 | |
2020 | Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial | Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG ; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garc?a Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.; Gettinger S.N.; Tiseo M.; Lin H.M.; Gupta N.; Hanley M.J.; Ni Q.; Zhang P.; Popat S. | Journal of Clinical Oncology | 235 | 196 | |
2021 | Brigatinib versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial | Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG ; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garcia Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.I.; Gettinger S.N.; Tiseo M.; Lin H.M.; Liu Y.; Vranceanu F.; Niu H.; Zhang P.; Popat S. | Journal of Thoracic Oncology | 160 | 119 | |
2009 | Chronic myeloid leukemia in Asia | Au W.Y.; Caguioa P.B.; Chuah C.; SZU-CHUN HSU ; Jootar S.; Kim D.-W.; Kweon I.-Y.; O'Neil W.M.; Saikia T.K.; Wang J. | International Journal of Hematology | 99 | 80 | |
2010 | Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy era | Kim D.-W.; Banavali S.D.; Bunworasate U.; Goh Y.-T.; Ganly P.; Huang H.; Irving I.; Jootar S.; Goh H.-G.; Koh L.-P.; Li W.; Naoe T.; Ng S.-C.; Purushotaman V.; Reksodiputro H.; Shih L.-Y.; JIH-LUH TANG ; Tojo A.; Wang J.; Wong R. | Leukemia Research | 36 | 27 | |
2008 | Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase | Cortes J.; Kim D.-W.; Raffoux E.; Martinelli G.; Ritchie E.; Roy L.; Coutre S.; Corm S.; Hamerschlak N.; JIH-LUH TANG ; Hochhaus A.; Khoury H.J.; Brümmendorf T.H.; Michallet M.; Rege-Cambrin G.; Gambacorti-Passerini C.; Radich J.P.; Ernst T.; Zhu C.; Van Tornout J.M.A.; Talpaz M. | Leukemia | 174 | 156 | |
2022 | Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer | Jänne P.A.; Baik C.; Su W.-C.; Johnson M.L.; Hayashi H.; Nishio M.; Kim D.-W.; Koczywas M.; Gold K.A.; Steuer C.E.; Murakami H.; CHIH-HSIN YANG ; Kim S.-W.; Vigliotti M.; Shi R.; Qi Z.; Qiu Y.; Zhao L.; Sternberg D.; Yu C.; Yu H.A. | Cancer discovery | 118 | 85 | |
2014 | First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial | CHIH-HSIN YANG ; Kang J.H.; Mok T.; Ahn M.-J.; Srimuninnimit V.; CHIA-CHI LIN ; Kim D.-W.; Tsai C.-M.; Barraclough H.; Altug S.; Orlando M.; Park K. | European Journal of Cancer | 41 | 40 | |
2021 | Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study | Park K.; Jӓnne P.A.; Kim D.-W.; Han J.-Y.; Wu M.-F.; Lee J.-S.; Kang J.-H.; Lee D.H.; Cho B.C.; CHONG-JEN YU ; Pang Y.K.; Felip E.; Kim H.; Baek E.; Noh Y.S. | Cancer | 18 | 10 | |
2020 | Osimertinib in patients with T790M-positive advanced non-small cell lung cancer: Korean subgroup analysis from phase II studies | Ahn M.-J.; Han J.-Y.; Kim D.-W.; Cho B.C.; Kang J.-H.; Kim S.-W.; CHIH-HSIN YANG ; Mitsudomi T.; Lee J.S. | Cancer Research and Treatment | 5 | 5 | |
2017 | Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component | CHIH-HSIN YANG ; Ahn M.-J.; Kim D.-W.; Ramalingam S.S.; Sequist L.V.; Su W.-C.; Kim S.-W.; Kim J.-H.; Planchard D.; Felip E.; Blackhall F.; Haggstrom D.; Yoh K.; Novello S.; Gold K.; Hirashima T.; Chia-Chi Lin ; Mann H.; Cantarini M.; Ghiorghiu S.; Jänne P.A. | Journal of Clinical Oncology | 454 | 443 | |
2021 | Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia—Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium | Shimizu T.; Kim D.-W.; Loong H.H.; CHIA-CHI LIN ; Ng M.C.H.; Yamamoto N.; Ma B.; Tan D.S.W. | Asia-Pacific Journal of Clinical Oncology | 2 | 1 | |
2020 | Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study | Tan D.S.-W.; Leighl N.B.; Riely G.J.; CHIH-HSIN YANG ; Sequist L.V.; Wolf J.; Seto T.; Felip E.; Aix S.P.; Jonnaert M.; Pan C.; Tan E.Y.; Ko J.; Moody S.E.; Kim D.-W. | The Lancet Respiratory Medicine | 40 | 37 | |
2020 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial | Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG ; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. | The Lancet Respiratory Medicine | 161 | 128 |